NCT04504760 - Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

March 18, 2021

Study Completion Date

March 18, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

ONO-2910

Single ascending dose of ONO-2910 will be administered orally.

DRUG

Placebo

Single dose of placebo will be administered orally.

DRUG

ONO-2910

Multiple ascending dose of ONO-2910 will be administered orally.

DRUG

Placebo

Multiple dose of placebo will be administered orally.

Trial Locations (1)

Tokyo Clinical Site 01, Tokyo